By Fineline Cube Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its first-in-class (FIC) Class 1 therapeutic biologic, loncomystatug deruxtecan (BL-B01D1/iza-bren), has received marketing approval from China’s National Medical Products Administration (NMPA) for recurrent/metastatic nasopharyngeal carcinoma (NPC) in patients who have failed at least two prior lines of systemic chemotherapy and a PD-1/PD-L1 inhibitor.
Regulatory Milestone Details
| Parameter | Detail |
|---|---|
| Company | Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) |
| Product | Loncomystatug deruxtecan (BL-B01D1/iza-bren) |
| Approval Authority | National Medical Products Administration (NMPA), China |
| Approval Date | June 23, 2026 |
| Indication | Recurrent/metastatic NPC (≥2 prior chemo lines + PD-1/PD-L1 inhibitor failure) |
| Drug Classification | First-in-class (FIC) Class 1 therapeutic biologic |
| Global Significance | World’s first EGFR×HER3 bispecific antibody-drug conjugate (ADC) approved for marketing |
Product Innovation Profile
- Mechanism: EGFR×HER3 bispecific antibody-drug conjugate (ADC) targeting dual receptor pathways simultaneously
- Therapeutic Breakthrough: Represents the first successful clinical application of bispecific ADC technology combining EGFR and HER3 targeting
- Target Population: Addresses high-unmet need in heavily pre-treated NPC patients with limited therapeutic options
- Development Status: Over 40 clinical trials conducted across China and the United States
Clinical Development Portfolio
Advanced Trial Portfolio:
- 19 Phase III studies (including Phase II/III) across multiple tumor types
- 7 NMPA Breakthrough Therapy Designations for various indications
- 2 NMPA Priority Reviews granted
- 1 FDA Breakthrough Therapy Designation in the United States
Additional NDA Submissions Pending:
- Recurrent or metastatic esophageal squamous cell carcinoma
- Locally advanced or metastatic triple-negative breast cancer
Strategic Market Implications
- Platform Validation: Successful approval validates Biokin’s bispecific ADC platform technology with potential applications across multiple solid tumors
- Competitive Differentiation: Dual EGFR×HER3 targeting provides unique mechanism compared to single-target ADCs and traditional therapies
- Commercial Opportunity: NPC represents significant market opportunity in Asia, with peak annual sales potential estimated at ¥2–3 billion ($280–420 million) in China alone
- Global Expansion Pathway: FDA Breakthrough Therapy Designation supports international development strategy beyond China
Development Context
This approval represents a major milestone for Chinese biotechnology innovation, demonstrating the capability to develop world-first bispecific ADC technologies. The extensive clinical program spanning 40 trials across two continents reflects Biokin’s commitment to comprehensive global development standards while addressing regionally prevalent cancers like nasopharyngeal carcinoma.
The rapid regulatory progression—supported by multiple breakthrough designations and priority reviews—highlights the significant unmet medical need in recurrent/metastatic NPC and the compelling clinical profile of loncomystatug deruxtecan.
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical development, and commercial expectations. Actual results may differ materially due to risks including market adoption rates, competitive dynamics, manufacturing scalability, and clinical trial outcomes in additional indications.-Fineline Info & Tech